Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

The Food and Drug Administration expanded its approval of Pfizer’s vaccine for a deadly respiratory virus to a new age group. The vaccine, called Abrysvo, has been approved for the prevention of ...

The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD).

Activist hedge fund manager Jeff Smith outlined his concerns about drugmaker Pfizer on Tuesday but stopped short of offering a solution — saying that's a job for the board of directors.

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE) has received U.S. Food and Drug Administration (FDA) approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, ABRYSVO®, to include ...

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. The layoffs come three months after the company axed 150 positions in Sanford following a high ...

NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...

There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's performance has not been good enough. Pfizer has been in an anomalous ...

NEW YORK (Reuters) - Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to ...

Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.